Healthcare & Life Sciences

Richard Close

Managing Director, Senior Analyst, Canaccord Genuity Inc. (US)

Richard Close has been a Senior Research Analyst for nearly 20 years and has been covering the healthcare technology and services sector for more than ten years. Prior to joining Canaccord Genuity, he was Managing Director at Avondale Partners from 2011 through 2015 and at Jefferies from 2003 through 2010. Prior to covering healthcare, he published research on the business services and education technology sectors while at Jefferies and SunTrust Robinson Humphrey. He has been recognized twice by the Wall Street Journal as a top-ten stock picker across all industries and earned “Best on the Street” in 2001 (Consumer Products & Services), 2003 (Consumer Services), and 2005 (Specialty Retailers & Services). Additionally, he has earned various top honors in StarMine/FT/Forbes rankings: as a top stock picker in 2005 (Commercial Services & Suppliers) and 2013 (Healthcare Technology); as a top earnings estimator in 2007 (Healthcare Technology); and as both a top stock picker and earnings estimator in 2009 (Healthcare Technology). 

Phone: 615.490.8501; Email:RClose@canaccordgenuity.com 

Allscripts Healthcare Solutions
athenahealth
Castlight Health 
Cerner Corporation
Civitas Solutions
CRH Medical Corporation
Envision Healthcare Corporation
Evolent Health 
HealthStream
Health Insurance Innovations 
HMS Holdings
MAXIMUS
NantHealth
Premier 
Teladoc

Arlinda Lee, Ph.D

Analyst, Canaccord Genuity Inc. (US)

Akari Therapeutics
Aquinox Pharmaceuticals
Blueprint Medicines 
Cara Therapeutics
Fibrocell Science
Halozyme
Karyopharm Therapeutics
NantKwest
Summit Therapeutics plc
SCYNEXIS 
Ultragenyx Pharmaceutical
vTv Therapeutics
Xencor
Zafgen 
Zymeworks 
Zynerba Pharmaceuticals  

Neil Maruoka

Analyst, Canaccord Genuity Corp. (Canada)

Neil joined the Life Sciences team at Canaccord in 2006 after several years in the biotechnology sector. Prior, Neil worked as an associate analyst covering both small and large-cap biotech and pharmaceutical companies. Neil began his career as an Investment Analyst at MDS Capital, one of the largest biotechnology-focused venture capital management firms in Canada. Neil graduated with an undergraduate degree in Life Sciences and a Masters degree in Physiology and Molecular Biology from Queen's University in Kingston, Ontario. He also holds an MBA from the Richard Ivey School of Business at the University of Western Ontario. Email: nmaruoka@canaccordgenuity.com; Phone: 1.416.869.3073

Aurora Cannabis Inc. 
Aurinia Pharmaceuticals
Canopy Growth Corp. 
Cardiome Pharma Corp.
Centric Health Corp.
Concordia Healthcare Corp.
Emblem Corp. 
Medical Facilities Corporation
Merus Labs International Inc.
Oncolytics Biotech Inc.
ProMetic Life Scieneces Inc.
Sienna Senior Living Inc.
Theratechnologies Inc.
TSO3 Inc. 
Valeant Pharmaceuticals International Inc.

Mark Massaro

Analyst, Canaccord Genuity Inc. (US)

Mark is a senior analyst covering the Diagnostics and Life Sciences Tools sector, with a focus on molecular diagnostics, point-of-care diagnostics, and reference labs. Mark joined Canaccord in 2011 as a senior associate analyst. Prior to Canaccord, Mark worked at Avondale Partners covering the health care services space, notably hospitals, reference labs, pharmacy benefit managers and health care REITs, as an associate analyst. Mark completed his Master's Degree in Business Administration, summa cum laude, from the FW Olin Graduate School of Business at Babson College and interned at Essex Investment Management and FinArc LLC in Boston. Mark earned his bachelor's degree in Economics and Spanish, cum laude, from the University of Massachusetts-Amherst.  Mark serves on the board of directors for the University of Massachusetts Economics Department and is a member of the Boston Security Analysts Society. Email: mmassaro@canaccordgenuity.com; Phone: 1.617.371.3769

Abaxis
Exact Sciences
GenMark Diagnostics
Genomic Health
Heska
Hologic
HTG Molecular Diagnostics
IDEXX Laboratories
Illumina 
Laboratory Corporation of America Holdings
Meridian Bioscience
Natera
OraSure Technologies
Quest Diagnostics
Quidel
T2 Biosystems
Vermillion 

Jason R. Mills

Analyst, Canaccord Genuity Inc. (US)

Mr. Mills has been a publishing sell-side analyst with coverage of medical devices for over 15 years. His areas of coverage include Cardiovascular, Imaging/Robotics, Ophthalmology and Women's Healthcare. Mr. Mills joined Canaccord Genuity from First Albany Capital where he was managing director and senior medical devices analyst, and he previously served as a vice president and senior med-tech analyst with Thomas Weisel Partners (now part of Stifel), Mr. Mills has earned awards for his stock picking, including the #2 ranked Medical Devices analyst in the The Wall Street Journal's 2011 "Best on the Street" Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. Mr. Mills holds a BA in Economics from Yale University and Master of Sports Administration from Ohio University.  Email: jmills@canaccordgenuity.com; Phone: 1.415.229.7166

AngioDynamics
AtriCure, Inc.
CryoLife
Edwards Lifesciences
Endologix
Intuitive Surgical
iRhythm Technologies 
LeMaitre Vascular
LivaNova PLC
Merit Medical Systems 
Nevro
Penumbra
STAAR Surgical Company
Tactile Systems Technology 

John Newman, Ph.D.

Principal, Canaccord Genuity Inc. (US)

John Newman, Ph.D. joined Canaccord Genuity in January 2013 and provides coverage of both the Biotechnology and Specialty Pharmaceuticals sectors. He has over eight years in equity research, with five as a senior analyst. Prior to Canaccord Genuity, John was a director at JMP Securities covering Specialty Pharmaceuticals and Biotechnology and a director at Citadel Securities covering Biotechnology. Before Citadel, John was a director covering Specialty Pharmaceuticals and Biotechnology at Oppenheimer and Company. John began his career on Wall Street at Merrill Lynch. John undertook a postdoctoral fellowship at University of Wisconsin Madison following his PhD where he also took several business courses in finance and accounting. He received a PhD from the University of Maryland in chemistry and a BS in chemistry from Loyola University. Email: jnewman@canaccordgenuity.com; Phone: 1.212.389.8042

Aduro Biotech
Advanced Accelerator Applications S.A 
Agios Pharmaceuticals
Aileron Therapeutics 
Aldeyra Therapeutics 
Aptose Biosciences Inc.
Atara Biotherapeutics
Celgene Corp. 
Gemphire Therapeutics 
Hutchison China MediTech Ltd. 
ImmunoGen
Palatin Technologies
Regeneron Pharmaceuticals
SAGE Therapeutics
Selecta Biosciences 
Seres Therapeutics 
Synergy Pharmaceuticals
TiGenix
Versartis

Matthijs Smith

Senior Analyst, Canaccord Genuity (Australia) Ltd.

Matthijs Smith joined Canaccord in September 2012 as a Senior Analyst specialising in Australian Life Science companies. Matthijs has over 8 years as Equities Analyst at Shaw Stockbroking, Lodge Partners and Patersons where he focused on emerging companies developing new pharmaceutical and medical device based therapies. Prior to moving into the capital markets, he held senior executive roles in the biotech industry as well as worked at the Boston Consulting Group. Matthijs has several year’s experience in medical research including a PhD from University of London, postdoctoral research at the University of Melbourne and worked as an assistant editor at the journal Nature. He also holds an MBA from Melbourne Business School in Australia. Email: matthijs.smith@canaccord.com.au; Phone: +61 3 8688 9107

Acrux Limited
AirXpanders Inc.
dorsaVi Limited
ImpediMed Limited
Nanosonics Limited
Osprey Medical Inc.
Pharmaxis Limited
Starpharma Holdings Ltd
Visioneering Technologies, Inc. 

 

Kyle Rose


Kyle Rose has been a member of Canaccord Genuity’s medical technology research team since 2010 and in 2016 assumed senior analyst responsibilities covering the orthopedics, diabetes, aesthetics and ENT sectors. Prior to joining Canaccord Genuity, Kyle worked as an associate product manager for Biomet Microfixation, a medical device manufacturer focusing on the craniomaxillofacial and cardiothoracic markets.

Kyle holds an MBA from the Kellogg School of Management at Northwestern University as well as a BA from the University of Michigan.  

 

ConforMIS
DexCom
Entellus Medical 
Globus Medical 
Histogenics Corp 
Insulet Corp 
Intersect ENT 
NuVasive
NxStage Medical 
Obalon Therapeutics
ReWalk Robotics 
Senseonics
Sientra
Smith & Nephew plc 

Stryker Corp 
Zimmer Biomet Holdings 

Dewey Steadman


Senior Specialty Pharma Analyst Dewey Steadman joined Canaccord Genuity from Akorn, a large-cap specialty generic pharmaceutical company, where he was the executive director of Investor Relations. Prior to that, he was director of IR for Actavis plc. Prior to his investor relations career, Dewey worked on the Specialty Pharma teams at J.P. Morgan, Morgan Stanley, and RBC, alongside some of the top analysts in the field. Dewey earned a dual degree in chemistry/biochemistry and in biology/molecular biology from the University of West Florida, and an MBA from the Rollins College Crummer Graduate School of Business. He is a CFA charterholder. Dewey is based in NY.  

Aceto Corporation
Aerie Pharmaceuticals
ANI Pharmaceuticals
Cardiome Pharma Corp.
Endo International
Impax Laboratories 
         
Inotek Pharmaceuticals
KemPharm
Lipocine 
Mallinckrodt plc 
Pacira Pharmaceuticals 
Perrigo Company 
Savara 
Teligent 

Matt Bottomley


Aphria Inc. 
iAnthus Capital Holdings, Inc. 
OrganiGram Holdings Inc. 
Supreme Pharmaceuticals Inc.
The Hydropothecary Corporation